Barinthus Biotherapeutics

Barinthus Biotherapeutics plc (Nasdaq: BRNS) is a clinical-stage biopharmaceutical company developing novel immunotherapies designed to guide and reprogram T cells to overcome autoimmunity, inflammatory disease, chronic viral infection, and cancer. Its lead SNAP-TI and SNAP-CI antigen-specific platforms and ChAdOx/MVA immunotherapeutic candidates power a five-program pipeline including VTP-1000 (celiac disease), VTP-300 (chronic hepatitis B), VTP-200 (high-risk HPV), VTP-850 (recurrent prostate cancer), and VTP-1100 (HPV-related cancer). The company was formed in 2021 through the merger of Oxford University spinout Vaccitech plc and NIH/Johns Hopkins spinout Avidea Technologies, and is headquartered in Germantown, Maryland with research facilities in the UK. It was surfaced as a portfolio company of Hongshan and added to the API Evangelist network. As a therapeutics company it publishes no public developer API, SDK, or agent surface.

Barinthus Biotherapeutics is profiled on the APIs.io network. Tagged areas include Company, Healthcare, Biotechnology, Biopharmaceutical, and Immunotherapy.

Barinthus Biotherapeutics’ developer surface includes support, product news, and 7 more developer resources.

🌐 Visit website 📡 Source on GitHub

11.5/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyHealthcareBiotechnologyBiopharmaceuticalImmunotherapyAutoimmuneOncologyClinical StageLife Sciences

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 11.5/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.9 / 20

Commercial Clarity 2.1 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/barinthus-biotherapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

Company 5

The organization behind the API

Website

About

News

Investors

LinkedIn

Other 1

Properties that don't map to a standard resource type

Pipeline

Pipeline

Source (apis.yml)

aid: barinthus-biotherapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/barinthus-biotherapeutics.png
name: Barinthus Biotherapeutics
description: 'Barinthus Biotherapeutics plc (Nasdaq: BRNS) is a clinical-stage biopharmaceutical company developing novel
  immunotherapies designed to guide and reprogram T cells to overcome autoimmunity, inflammatory disease, chronic viral infection,
  and cancer. Its lead SNAP-TI and SNAP-CI antigen-specific platforms and ChAdOx/MVA immunotherapeutic candidates power a
  five-program pipeline including VTP-1000 (celiac disease), VTP-300 (chronic hepatitis B), VTP-200 (high-risk HPV), VTP-850
  (recurrent prostate cancer), and VTP-1100 (HPV-related cancer). The company was formed in 2021 through the merger of Oxford
  University spinout Vaccitech plc and NIH/Johns Hopkins spinout Avidea Technologies, and is headquartered in Germantown,
  Maryland with research facilities in the UK. It was surfaced as a portfolio company of Hongshan and added to the API Evangelist
  network. As a therapeutics company it publishes no public developer API, SDK, or agent surface.'
url: https://raw.githubusercontent.com/api-evangelist/barinthus-biotherapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- hongshan
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Healthcare
- Biotechnology
- Biopharmaceutical
- Immunotherapy
- Autoimmune
- Oncology
- Clinical Stage
- Life Sciences
apis: []
common:
- type: DomainSecurity
  url: security/barinthus-biotherapeutics-domain-security.yml
- type: Website
  url: https://www.barinthusbio.com/
- type: About
  url: https://www.barinthusbio.com/about/
- type: Pipeline
  url: https://www.barinthusbio.com/pipeline/
- type: Support
  url: https://www.barinthusbio.com/contact/
- type: News
  url: https://investors.barinthusbio.com/news-filings/press-releases
- type: Investors
  url: https://investors.barinthusbio.com/
- type: PrivacyPolicy
  url: https://www.barinthusbio.com/data-protection-policy/
- type: LinkedIn
  url: https://www.linkedin.com/company/barinthusbiotherapeutics
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence